jiangsu aidea pharmaceutical group co , ltd
Jiangsu Aidi Pharmaceutical Group Co., Ltd.-Aidi Pharmaceutical
Jiangsu Aidi Pharmaceutical Group Co., Ltd. was founded in 2009 and was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2020 (stock code: 688488.SH). It is a national high-tech enterprise and a national-level specialized and new small giant enterprise. The company integrates the R&D, production and sales of innovative drugs and is deeply involved in two core business areas: focusing on anti-AIDS drugs as the core development track, achieving full chain coverage from treatment to prevention, and striving to build a national brand in the anti-HIV field in China; focusing on the field of human protein biopharmaceuticals, it has the most competitive human protein industry chain in China.
- Type
- Manufacturer
- Location
- Yangzhou, China
- Website
- https://www.aidea.com.cn/
- Categories
- Pharmaceutical Manufacturing, Chemicals & Plastics, Supplements & Wellness
Listed in a source registry
Verified facts
- corporate-mail-on-domain (green), checked 2026-08-04 Mail server of the company domain
- web-presence-since (green), checked 2026-08-03 Internet Archive (Wayback)
- debarment-clear (green), checked 2026-08-04 OpenSanctions
- sanctions-clear (green), checked 2026-08-04 OpenSanctions
- lei-lapsed (amber), checked 2026-08-04 GLEIF
Import rules for these goods
- Food supplements sold in the EU follow Directive 2002/46/EC: most member states require a notification to the national authority before the first sale. European Commission (supplements)
- Chemical substances imported into the EU above 1 tonne/year must be REACH-registered. ECHA (REACH)
- Medicines imported into the EU must come from a site holding an EU GMP certificate, and the importer needs a manufacturing/import authorisation. European Medicines Agency (GMP)